Arie Belldegrun Overview

  • Investor Type
  • Angel
  • Status
  • Active
  • Professionals
  • 1
  • Investments
  • 5
  • Exits
  • 4

Arie Belldegrun General Information


Mr. Arie Belldegrun is co-Founder and Senior Managing Director of Vida Ventures. He is also a Co-Founder of Bellco Capital where he serves as Chairman. He is also Executive Chairman and Co-Founder of Allogene Therapeutics, a clinical-stage biotechnology company focused on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. A visionary entrepreneur, he founded Kite Pharma, a biopharmaceutical company engaged in the development of innovative cancer immunotherapies, where he served as Chairman, President, and Chief Executive Officer until the acquisition of Kite by Gilead Sciences in October 2017. He has had a distinguished tenure in the life sciences, having been closely involved with the founding and advancement of several successful biopharmaceutical companies including Cougar Biotechnology and Agensys. Abiraterone, developed by Cougar, is a mainstay of therapy for patients with metastatic prostate cancer. He currently serves as Chairman of Two River Group, UroGen Pharma, Kronos Bio, and Bellco Capital, and as co-Chairman of Breakthrough Properties. He is a Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA, he was at the National Cancer Institute/NIH as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. He completed his MD at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in Immunology at the Weizmann Institute of Science, and his residency in urologic surgery at Harvard Medical School. He has authored several books on oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy, and cancer vaccines. He is certified by the American Board of Urology and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons.

Contact Information

Investor Status
Actively Seeking New Investments
Primary Investor Type
Angel (individual)
Primary Office
  • Los Angeles, CA
  • United States

Arie Belldegrun Investments (5)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Kronos Bio 13-Jul-2019 Early Stage VC 00000 Biotechnology Pre-Clinical Trials 0000 0000000000 00
000000 000 23-May-2018 0000 00000 0000 Biotechnology Pre-Clinical Trials 0000 0000000000 00
000000 000 18-Oct-2017 00000 00000 000.00 Drug Delivery Generating Revenue/Not Profitable 0000 0000000000 00
Kite Pharma 20-Jun-2014 IPO 00000 Biotechnology Profitable 0000 0000000000 00
Cell Design Labs Early Stage VC 00.00 Biotechnology Generating Revenue 0000 0000000000 00
To view Arie Belldegrun’s complete investments history, request access »
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Arie Belldegrun Exits (4)

Company Name Exit Date Exit Type Exit Size
Kronos Bio 09-Oct-2020 IPO 00000
000000 000 28-Jun-2018 000 000.00
Cell Design Labs 01-Dec-2017 Merger/Acquisition 00000
Kite Pharma 03-Oct-2017 Merger/Acquisition 0000
To view Arie Belldegrun’s complete exits history, request access »

Arie Belldegrun Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Arie Belldegrun Team (1)

Name Title Deals Funds Boards Office
Arie Belldegrun MD Angel Investor 00 0 00 Los Angeles, CA
To view Arie Belldegrun’s complete team members history, request access »

Arie Belldegrun Co-Investors (10)

Name With Exits Lead Partner Series Industry
GV 1 0 Series chart Industry bar
Nextech Invest 0 0 Series chart Industry bar
Omega Funds 0 0 Series chart Industry bar
Polaris Partners 0 0 Series chart Industry bar
The Invus Group 0 0 Series chart Industry bar
You’re viewing 5 of 10 co-investors. Get the full list »